Navigation Links
Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
Date:11/20/2007

orward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ab
'/>"/>
SOURCE Repligen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... 2015 Researchers say working around asbestos-containing ... sheet metal workers contract malignant mesothelioma. Surviving Mesothelioma has ... its website. Click here to read it now. ... and Training monitored 17,345 sheet metal workers from 1986 ... them died of mesothelioma or another asbestos-related disease ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 ERISAPros ... King and Carolyn Roddy to the professional staff of ... Compliance, graduated from The Ohio State University-Mortiz College of ... years of experience working with several Fortune 500 companies ... the area of corporate benefits. Her experiences range from ...
(Date:2/28/2015)... In recent years Medical Marijuana has continuously ... as a way for them to expand their patient base ... medicine. Since the FDA still lists Cannabis as a Schedule ... licensed physicians that can help guide them when recommending ... in Santa Cruz, CA is a leader in the ...
(Date:2/28/2015)... 2015 The Heart Fit Clinic started ... of the machine. The Heart Fit Clinic is also ... a franchise model. The goal is to scale the ... disease. To buy External Counterpulsation machines can ... individuals through this process and achieve the desired results. ...
(Date:2/28/2015)... Indosoft Inc , developers of ... are pleased to announce the development of Q-Suite 5.9. ... versions of Q-Suite, this new version will include enhancements ... new features to the leading edge call center software. ... will add features to enhance security and protection. Administrators ...
Breaking Medicine News(10 mins):Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2
... immune system, says a study conducted by Spanish researchers . ... C, B-complex vitamins and has good doses of minerals like ... known that potatoes are good for bowel health. ... particularly if eaten cold or in a salad, the researchers ...
... to the coastal Spanish town of Altea to get Oslo-funded ... to fractured bones. ,"In Norway it is cold ... why they are better off here," the tanned head of ... ,The rehabilitation centre was set up and is run by ...
... are an indicator of an industry's health, then the turnout ... and spirits fair, confirms the sector is doing nicely, if ... this year's show, a two-yearly event in Bordeaux, a three ... for Vinexpo by the London-based International Wine and Spirit Record ...
... with a life-threatening illness, a young Indian American is hard ... 10 as very few South Asians are listed in the ... Chakravarthy was diagnosed with a disease known as Acute Myelogenous ... bone marrow, the South Asian community has come together nationwide ...
... up with a partner in Harley Street - a ... are frequented by celebrities - and is introducing ... into tie-up based on her franchise system with the ... Ayurveda on Harley Street is indicative of the increasing ...
... Fey has launched an entirely new kind of healthcare ... culture of prevention throughout America and the world -- ... to one that encourages people to take early steps ... ,This message appears this week in a full-page ad in ...
Cached Medicine News:Health News:Intake of Potatoes Boosts the Immune System 2Health News:Norwegians Take in the Sun in Spain on Doctors' Orders 2Health News:World Wine Sales Brisk, but French Producers Hungover 2Health News:World Wine Sales Brisk, but French Producers Hungover 3Health News:South Asians Seek Bone Marrow for Young Indian American 2Health News:Shahnaz Hussain Takes Ayurveda to London's Harley Street 2Health News:U.S. Preventive Medicine(R) Encourages the International Community to Embrace Prevention 2
(Date:2/27/2015)... Feb. 27, 2015 Pharmaceutical and biotech marketers ... products for the same indication. This can be a ... to prevent one of their brands from gaining market ... to recent research by benchmarking firm, Best Practices, LLC, ... brands rather than together as part of a franchise. ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... published in the Proceedings of the National ... showed when ibrutinib (IMBRUVICA ® ) was combined ... of tumor growth was enhanced suggesting a greater ... cancers and solid tumors with the combination. IMBRUVICA ...
(Date:2/27/2015)... YORK , Feb. 27, 2015 Securities ... the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... $158.00 per share. Concerned SLXP investors are encouraged to ... The investigation focuses upon the shareholder ... agreement, Salix shareholders would receive only $158.00 per share ...
Breaking Medicine Technology:New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide smooth handle with polished finish....
Smooth 90 degree jaws with locking screw maintain proper stretch of sleeve for securing silicone bands....
Ergotec Vetriretinal Instrument System. Extra fine angled tips (3 mm). 20 ga. shaft tapering to 23 ga., 10 mm from tip. Overall length from rear rotation knob to tip....
Medicine Products: